- Dividend Brief
- Posts
- A Pantry Giant Eyes a Deal That Could Reshape the Kitchen
A Pantry Giant Eyes a Deal That Could Reshape the Kitchen
Some deals are about trimming around the edges.
This one could redefine what sits at the center of the modern kitchen. Read on for all the details.
Learn More (Sponsored)
In 1943, a teenage Warren Buffett put $114 into a special type of account called
"The 29% Account."
Today, that single, $114 investment would be worth over $15 million.
Your bank never told you about this.
Click Here to See How It Works
Oil and Gas
ExxonMobil Is Not Slowing Down in Guyana, It Is Speeding Up
Exxon Mobil Corporation (NYSE: XOM) is accelerating the pace of its offshore oil projects in Guyana, with a fifth floating production platform nearly complete and expected to leave Singapore soon for South American waters. Originally, ExxonMobil did not expect to recover its costs in Guyana until 2027. Rising oil prices have pulled that timeline forward to this year.
Guyana Changed ExxonMobil's Future
A decade ago, Guyana was barely on the global oil map. ExxonMobil's discoveries offshore transformed it into one of the most significant oil regions found in a generation. The reservoirs are massive, the crude quality is high, and the production costs are among the lowest in the world.
Each new platform adds hundreds of thousands of barrels per day to ExxonMobil's output. That kind of growth from a single region is extremely rare in today's energy industry.
Seven Projects in One Country
Five platforms built, a sixth confirmed, and a seventh in accelerated development. That concentration in a single country is both a strength and a commitment. ExxonMobil has made Guyana central to its growth strategy in a way that no other region matches right now.
The scale here deserves your full attention. ExxonMobil is not just drilling wells in Guyana. It is constructing an entire offshore production network that could define the company's output for the next two decades.
XOM currently trades at $161 and pays a dividend of $4.12 per share, a yield of 2.56%.
Pharmaceuticals
Lilly's Next Blockbuster Just Cleared Its Biggest Test Yet
Eli Lilly (NYSE: LLY) just scored a major win for retatrutide, its next-generation obesity drug. The treatment passed its first late-stage trial.
Patients with Type 2 diabetes saw meaningful drops in blood sugar. They also lost nearly 17% of their body weight at the highest dose over 40 weeks. This is Lilly building a third pillar beneath the world's most dominant obesity franchise.
Three Weapons, One Company
Lilly already sells Zepbound, the injectable that keeps breaking sales records. An obesity pill called orforglipron is moving through development behind it. Retatrutide now sits as the most powerful option in the pipeline.
Most companies celebrate having one successful obesity product. Lilly is stacking three. That depth gives it something no competitor can match right now.
The Lead Keeps Growing
Lilly is not coasting on Zepbound's success. It is building a portfolio that covers injections, pills, and now a next-generation treatment that outperforms earlier treatments.
Follow that trajectory, and the picture gets clear fast. Lilly is not just leading the obesity market; it is shaping it. It is engineering a gap that gets wider with every successful trial. That kind of momentum deserves your attention because it is redrawing the entire pharmaceutical landscape.
LLY currently trades at $919 and pays a dividend of $6.92 per share, a yield of 0.75%.
Start Now (Sponsored)
Major changes in the financial system are causing many savers to take a closer look at how they protect their retirement wealth.
If you’re concerned about inflation, digital financial infrastructure, or long-term control over your savings, Reagan Gold Group’s free Wealth Protection Guide can help you explore your options.
It explains a strategy many Americans are considering to add more stability and diversification to their retirement planning.
Click here to access the free guide
P.S. No pressure—just straightforward information to help you make a more informed decision.
*Reagan Gold Group does not give financial or tax advice. Price of metals fluctuates and there are no guarantees of performance.
Industrial
Is This How Honeywell Becomes Essential to Every Factory on Earth?
Honeywell International (NASDAQ: HON) just launched a commercial AI product that sits inside industrial control rooms and predicts problems before they happen. The system analyzes years of historical data alongside live operations to spot risks tied to safety, equipment reliability, and production efficiency.
During pilot testing with major energy companies, it identified potential incidents five to ten minutes before they occurred. That does not sound like much time. In a refinery or chemical plant, it is the difference between a routine fix and a catastrophic shutdown.
From Pilot to Product
Honeywell tested this with some of the world's largest energy companies. The results proved the system works in real operating environments, not just in a lab. It is now commercially available to any industrial facility running Honeywell's existing control systems.
The smartest part is what it does not require. No major infrastructure changes. No ripping out existing equipment. It plugs into what is already there and makes it smarter. That kind of simplicity is what takes your product from an interesting demo to an industry standard.
This Is Honeywell's Bigger Play
Every industrial facility that adopts this becomes harder for competitors to displace. You start to understand why Honeywell keeps investing in digital tools. Each one makes the company stickier in its operations, which cannot afford to switch.
HON currently trades at $225 and pays a dividend of $4.76 per share, a yield of 2.11%.
Dividend Stocks Worth Watching
Novo Nordisk (NYSE: NVO) has secured FDA approval for a higher-dose version of its blockbuster weight-loss drug Wegovy, marking a key step in its effort to close the gap with rival Eli Lilly in the fast-growing obesity market.
The new dose delivers significantly stronger results, with patients losing more than 20% of their body weight in clinical trials, compared with around 15% on the standard version. That improved efficacy is central to Novo’s strategy, as Lilly's competing drug has gained traction with both doctors and patients.
The approval gives Novo a more competitive offering and expands treatment options for patients who have not reached their targets on lower doses. It also comes under a faster FDA review pathway, highlighting the importance of obesity treatments as a public health priority.
For investors, this is about defending a high-growth franchise. If the higher-dose Wegovy can regain momentum, it could help Novo stabilise market share and sustain the strong revenue streams that underpin its long-term growth story. NVO pays a $1.27 dividend, with a 6.94% yield.
McCormick & Company, Inc. (NYSE: MKC) could be lining up a transformative deal by entering discussions with Unilever about a potential acquisition of its food business.
The move would bring together a powerhouse portfolio of pantry staples, combining McCormick's spices and sauces with major global brands like Hellmann's and Knorr, as well as well-known regional names. It marks a potential turning point for Unilever, which has been steadily stepping back from food over the past decade as it reshapes its broader portfolio.
For McCormick, the opportunity is clear. Expanding into complementary categories could deepen its presence in everyday cooking and strengthen its position across global kitchens. For Unilever, it represents another step toward focusing on higher-growth, non-food segments.
For dividend investors, this is a classic scale play. If executed well, a deal like this could enhance McCormick’s pricing power, broaden its revenue base, and support more resilient cash flows. This kind can underpin steady dividend growth over time.
Silgan Holdings, Inc. (NYSE: SLGN) is exploring a potential takeover of Gerresheimer, signalling a possible opportunistic move into healthcare packaging amid significant pressure on the target.
Gerresheimer’s shares have fallen sharply from prior highs and are down heavily this year, weighed by accounting concerns and an ongoing regulatory probe in Germany. That backdrop appears to have opened the door for interest from strategic buyers, with Silgan reportedly working with advisers as it evaluates a possible bid.
There is no certainty that a deal will materialise, but the situation highlights how market dislocations can create acquisition opportunities. For Silgan, expanding into medical packaging could offer exposure to more stable, higher-margin end markets compared to traditional consumer packaging.
For dividend investors, this is a watchlist moment. If executed well, a deal could strengthen Silgan’s long-term growth profile and diversify its revenue base, supporting more resilient cash flows, but it also introduces execution risk that investors will want to monitor closely. SLGN pays a 20-cent dividend, yielding 2.07%.
Dividend Increases
TNET has increased its dividend to 29 cents, up 5.45%. Its new yield is 3.14%.
WSM has raised its dividend to 76 cents, a rise of 15.15%. Its new yield is 1.65%.
EQR has boosted its dividend to 70 cents, a lift of 1.44%. Its new yield is 4.74%.
INDB has increased its dividend to 64 cents, a growth of 8.47%. Its new yield is 3.44%.
Dividend Decreases
WB has cut its dividend to 61 cents, a 25.61% decline. Its new yield is 7.06%.
Free Seat (Sponsored)
The 2026 Gold & Silver Summit goes live in just days.
Public investors are being whipsawed by headlines.
Meanwhile, experienced buyers are quietly positioning.
Supply deficits. Currency pressure. Long-term structural shifts.
We’ll break it all down — live.
[SAVE YOUR FREE SEAT NOW]
P.S. Seats are filling. Register before it’s too late.
Poll: Which is harder to admit? |
Upcoming Dividend Payers
PYPL’s ex-dividend date for the forthcoming 14-cent payment is 03/25/26.
HAL’s ex-dividend date for the forthcoming 17-cent payment is 03/25/26.
HD’s ex-dividend date for the forthcoming $2.33 payment is 03/26/26.
QCOM’s ex-dividend date for the forthcoming 89-cent payment is 03/26/26.
Everything Else
FedEx has agreed to a four-year, $500,000 commitment to the business schools of Tennessee State University, Jackson State University, Mississippi Valley State University, and LeMoyne-Owen College to advance opportunities for HBCU students.
Home Depot has teamed up with David Beckham to launch its World Cup Sweepstakes, with a trip to the NYC final up for grabs.
Josh D’Amaro has outlined his vision for Disney after taking the reins earlier this week at the 2026 Annual Meeting of Shareholders.
Insurer Chubb has been named as the lead partner in the U.S. International Development Finance Corporation's $20 billion Maritime Reinsurance Plan for ships sailing through the Strait of Hormuz.
That’s all for today’s edition of the Dividend Brief.
Thanks for reading, and if you have any feedback or dividend stocks you want me to take a look at, just reply to this email!
—Noah Zelvis
DividendBrief.com